118 related articles for article (PubMed ID: 7516363)
21. Efficacy of adenine arabinoside 5'-monophosphate in kidney recipients with chronic active hepatitis B: a pilot study.
Pol S; Saltiel C; Legendre C; Carnot F; Driss F; Berthelot P; Bréchot C; Ruet C; Kreis H
Transplant Proc; 1993 Feb; 25(1 Pt 2):1446-9. PubMed ID: 7680158
[No Abstract] [Full Text] [Related]
22. Therapy of chronic type B hepatitis with adenine arabinoside and adenine arabinoside monophosphate.
Hoofnagle JH
J Hepatol; 1986; 3 Suppl 2():S73-80. PubMed ID: 2439579
[TBL] [Abstract][Full Text] [Related]
23. Effects of adenine arabinoside on serum and intrahepatic replicative forms of duck hepatitis B virus in chronic infection.
Hirota K; Sherker AH; Omata M; Yokosuka O; Okuda K
Hepatology; 1987; 7(1):24-8. PubMed ID: 3804202
[TBL] [Abstract][Full Text] [Related]
24. Interferon vs. adenine arabinoside 5'-monophosphate in patients with anti-HBe-positive chronic hepatitis.
Buti M; Jardi R; Rodriguez-Frias F; Allende H; Cotrina M; Esteban R; Guardia J
J Med Virol; 1996 Aug; 49(4):325-8. PubMed ID: 8877766
[TBL] [Abstract][Full Text] [Related]
25. Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. A randomized, double-blinded, placebo-controlled trial.
Garcia G; Smith CI; Weissberg JI; Eisenberg M; Bissett J; Nair PV; Mastre B; Rosno S; Roskamp D; Waterman K
Ann Intern Med; 1987 Sep; 107(3):278-85. PubMed ID: 2441633
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy of adenine arabinoside 5' monophosphate and prednisone withdrawal followed by adenine arabinoside 5' monophosphate in the treatment of chronic active hepatitis type B.
Perrillo RP; Regenstein FG; Bodicky CJ; Campbell CR; Sanders GE; Sunwoo YC
Gastroenterology; 1985 Mar; 88(3):780-6. PubMed ID: 2578421
[TBL] [Abstract][Full Text] [Related]
27. Development and application of an in vitro model for screening anti-hepatitis B virus therapeutics.
Lampertico P; Malter JS; Gerber MA
Hepatology; 1991 Mar; 13(3):422-6. PubMed ID: 1705531
[TBL] [Abstract][Full Text] [Related]
28. A cell culture assay for compounds which inhibit hepatitis B virus replication.
Korba BE; Milman G
Antiviral Res; 1991; 15(3):217-28. PubMed ID: 1716089
[No Abstract] [Full Text] [Related]
29. [Preliminary clinic observation on the inhibition of HBV by receptor-targeted drug L-HSA-AraAMP].
Wang H; Zhang L; Wang X
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1998 Mar; 12(1):12-4. PubMed ID: 12515162
[TBL] [Abstract][Full Text] [Related]
30. The pathogenesis of vacuoles produced in rat and mouse liver cells by a conjugate of adenine arabinoside monophosphate with lactosaminated albumin.
Fiume L; Betts CM; Busi C; Corzani S; Derenzini M; Di Stefano G; Mattioli A
J Hepatol; 1992 Jul; 15(3):314-22. PubMed ID: 1447497
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic activity of vidarabine in symptomatic chronic active hepatitis related to HBV.
Trépo C; Ouzan D; Fontanges T; Chevallier M; Chossegros P; Degos F; Chevallier P; Hantz O
J Hepatol; 1986; 3 Suppl 2():S97-105. PubMed ID: 2439581
[TBL] [Abstract][Full Text] [Related]
32. Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection.
Weller IV; Lok AS; Mindel A; Karayiannis P; Galpin S; Monjardino J; Sherlock S; Thomas HC
Gut; 1985 Jul; 26(7):745-51. PubMed ID: 2410328
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy with ARA-AMP and interferon of chronic active hepatitis B. Interim analysis of an ongoing study.
Trépo C; Rougier P; Bizollon T; Poupon R; Zarski JP; Quinton A; Miguet JP; Causse X; Chossegros P; Chevallier M
J Hepatol; 1991; 13 Suppl 1():S3. PubMed ID: 1720439
[No Abstract] [Full Text] [Related]
34. Recurrence of hepatitis B in liver transplants treated with antiviral therapy.
Marzano A; Debernardi-Venon W; Smedile A; Brunetto MR; Torrani Cerenzia MR; Actis GC; Zamboni F; Ghisetti V; Piantino P; David E; Salizzoni M; Rizzetto M
Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):77-81. PubMed ID: 9615271
[TBL] [Abstract][Full Text] [Related]
35. Treatment of the chronic hepatitis B virus carrier state.
Lever AM
J Infect; 1988 May; 16(3):221-9. PubMed ID: 2456355
[TBL] [Abstract][Full Text] [Related]
36. A review of the efficacy of adenine arabinoside and lymphoblastoid interferon in the Royal Free Hospital studies of hepatitis B virus carrier treatment: identification of factors influencing response rates.
Thomas HC; Scully LJ; Lever AM; Yap I; Pignatelli M
Infection; 1987; 15 Suppl 1():S26-31. PubMed ID: 2439462
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis B-associated membranous glomerulonephritis treated with adenine arabinoside monophosphate.
Esteban R; Buti M; Vallés M; Allende H; Guardia J
Hepatology; 1986; 6(4):762-3. PubMed ID: 2426174
[No Abstract] [Full Text] [Related]
38. Liver targeting of nucleoside analogues coupled to galactosyl terminating macromolecules: a new approach to the treatment of a chronic viral hepatitis.
Fiume L; Verme G
Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):275-80. PubMed ID: 9646223
[TBL] [Abstract][Full Text] [Related]
39. Vidarabine monophosphate and human leukocyte interferon in chronic hepatitis B infection.
Smith CI; Kitchen LW; Scullard GH; Robinson WS; Gregory PB; Merigan TC
JAMA; 1982 Apr; 247(16):2261-5. PubMed ID: 6175774
[TBL] [Abstract][Full Text] [Related]
40. Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study.
Bassendine MF; Chadwick RG; Salmeron J; Shipton U; Thomas HC; Sherlock S
Gastroenterology; 1981 May; 80(5 pt 1):1016-22. PubMed ID: 7009310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
